| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash and cash equivalents | $4.6M-47.6% | $8.7M-30.7% | $12.6M-4.1% | $13.2M-79.3% | $63.5M+285.6% | $16.5M+219.3% | $5.2M |
| Marketable securities | $52.2M+20.7% | $43.2M+197.5% | $14.5M-50.1% | $29.1M+386.3% | $6.0M-78.4% | $27.8M-61.8% | $72.8M |
| Accounts receivable | $37K-50.7% | $75K+188.5% | $26K-95.6% | $588K | — | — | — |
| Prepaid and other current assets | $1.4M-39.7% | $2.4M+203.2% | $781K+1.0% | $773K-42.9% | $1.4M+25.7% | $1.1M-20.9% | $1.4M |
| Total current assets | $58.2M+7.0% | $54.4M+94.6% | $28.0M-36.0% | $43.7M-38.8% | $71.3M+57.3% | $45.3M-42.9% | $79.3M |
| Property and equipment, net | $220K+45.7% | $151K-36.0% | $236K-33.1% | $353K-21.7% | $451K-50.2% | $906K-38.0% | $1.5M |
| Operating lease right-of-use asset | $839K-28.7% | $1.2M+2.4% | $1.1M-48.2% | $2.2M-30.5% | $3.2M+93.6% | $1.6M-29.2% | $2.3M |
| Investment in Angel Pharmaceuticals | $11.0M-12.4% | $12.5M-22.2% | $16.1M-26.3% | $21.9M-36.2% | $34.3M-7.9% | $37.2M | — |
| Other assets | $855K+35.3% | $632K+610.1% | $89K-31.0% | $129K-45.3% | $236K-43.0% | $414K-19.3% | $513K |
| Total assets | $71.1M+3.2% | $68.9M+51.3% | $45.6M-33.2% | $68.2M-37.7% | $109.5M+28.0% | $85.5M+2.3% | $83.6M |
| Accounts payable | $2.5M-3.5% | $2.6M+69.3% | $1.5M-22.8% | $2.0M+26.3% | $1.6M-54.9% | $3.5M+41.6% | $2.4M |
| Operating lease liability | $534K-43.0% | $937K-31.8% | $1.4M+11.9% | $1.2M-52.8% | $2.6M+111.1% | $1.2M-46.7% | $2.3M |
| Accrued and other liabilities | $6.5M+74.1% | $3.7M-6.2% | $4.0M-47.4% | $7.5M+6.6% | $7.1M-6.9% | $7.6M+10.2% | $6.9M |
| Warrant liability | $28.9M | — | — | — | — | — | — |
| Total current liabilities | $9.4M-73.5% | $35.4M+415.4% | $6.9M-36.1% | $10.8M+10.9% | $9.7M-20.2% | $12.1M+18.8% | $10.2M |
| Total liabilities | $9.9M-72.7% | $36.3M+429.0% | $6.9M-43.3% | $12.1M-1.4% | $12.3M-8.1% | $13.4M+6.7% | $12.5M |
| Preferred stock: $0.0001 par value; 10,000,000 shares authorized at December 31, 2025 and December 31, 2024; 0 shares issued and outstanding at each of December 31, 2025 and December 31, 2024 | — | — | $0 | — | — | — | — |
| Common stock: $0.0001 par value; 290,000,000 shares authorized at December 31, 2025 and December 31, 2024; 74,696,629 and 67,899,779 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively | $7K+0.0% | $7K+40.0% | $5K+0.0% | $5K+0.0% | $5K+66.7% | $3K+0.0% | $3K |
| Additional paid-in capital | $474.4M+10.1% | $430.9M+15.1% | $374.4M+2.7% | $364.4M+0.7% | $361.7M+22.5% | $295.3M+2.4% | $288.2M |
| Accumulated other comprehensive loss | -$896K+30.4% | -$1.3M-33.2% | -$967K-71.8% | -$563K-130.1% | $1.9M+46625.0% | $4K-86.2% | $29K |
| Accumulated deficit | -$412.3M-3.8% | -$397.0M-18.6% | -$334.7M-8.8% | -$307.7M-15.5% | -$266.4M-19.4% | -$223.1M-2.8% | -$217.1M |
| Total stockholders' equity | $61.2M+87.9% | $32.6M-15.8% | $38.7M-31.1% | $56.1M-42.2% | $97.2M+34.7% | $72.1M+1.5% | $71.1M |
| Total liabilities and stockholders' equity | $71.1M+3.2% | $68.9M+51.3% | $45.6M-33.2% | $68.2M-37.7% | $109.5M+28.0% | $85.5M+2.3% | $83.6M |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Source: SEC EDGAR 10-K and 10-Q filings. Up to 10 years annual / 16 quarters shown.